全文获取类型
收费全文 | 2567篇 |
免费 | 159篇 |
国内免费 | 16篇 |
专业分类
耳鼻咽喉 | 26篇 |
儿科学 | 45篇 |
妇产科学 | 80篇 |
基础医学 | 244篇 |
口腔科学 | 58篇 |
临床医学 | 312篇 |
内科学 | 418篇 |
皮肤病学 | 22篇 |
神经病学 | 151篇 |
特种医学 | 196篇 |
外科学 | 344篇 |
综合类 | 63篇 |
一般理论 | 4篇 |
预防医学 | 349篇 |
眼科学 | 125篇 |
药学 | 147篇 |
肿瘤学 | 158篇 |
出版年
2021年 | 37篇 |
2020年 | 17篇 |
2019年 | 44篇 |
2018年 | 47篇 |
2017年 | 30篇 |
2016年 | 30篇 |
2015年 | 45篇 |
2014年 | 61篇 |
2013年 | 84篇 |
2012年 | 86篇 |
2011年 | 111篇 |
2010年 | 82篇 |
2009年 | 81篇 |
2008年 | 103篇 |
2007年 | 98篇 |
2006年 | 105篇 |
2005年 | 88篇 |
2004年 | 77篇 |
2003年 | 76篇 |
2002年 | 89篇 |
2001年 | 59篇 |
2000年 | 78篇 |
1999年 | 74篇 |
1998年 | 37篇 |
1997年 | 38篇 |
1996年 | 40篇 |
1995年 | 32篇 |
1994年 | 25篇 |
1993年 | 22篇 |
1992年 | 45篇 |
1991年 | 46篇 |
1990年 | 47篇 |
1989年 | 44篇 |
1988年 | 35篇 |
1987年 | 37篇 |
1986年 | 37篇 |
1985年 | 37篇 |
1984年 | 40篇 |
1983年 | 71篇 |
1982年 | 64篇 |
1981年 | 57篇 |
1980年 | 63篇 |
1979年 | 37篇 |
1978年 | 36篇 |
1977年 | 38篇 |
1976年 | 25篇 |
1974年 | 21篇 |
1973年 | 18篇 |
1970年 | 15篇 |
1966年 | 22篇 |
排序方式: 共有2742条查询结果,搜索用时 15 毫秒
1.
Kaela M. Varberg Khursheed Iqbal Masanaga Muto Mikaela E. Simon Regan L. Scott Keisuke Kozai Ruhul H. Choudhury John D. Aplin Rebecca Biswell Margaret Gibson Hiroaki Okae Takahiro Arima Jay L. Vivian Elin Grundberg Michael J. Soares 《Proceedings of the National Academy of Sciences of the United States of America》2021,118(10)
2.
3.
Xinyu Li Yongwei Su Katie Hege Gerard Madlambayan Holly Edwards Tristan Knight Lisa Polin Juiwanna Kushner Sijana H. Dzinic Kathryn White Jay Yang Regan Miller Guan Wang Lijing Zhao Yue Wang Hai Lin Jeffrey W. Taub Yubin Ge 《Haematologica》2021,106(5):1262
Venetoclax is a promising agent in the treatment of acute myeloid leukemia (AML), though its antileukemic activity is limited to combination therapies. Mcl-1 downregulation, Bim upregulation, and DNA damage have been identified as potential ways to enhance venetoclax activity. In this study, we combine venetoclax with the dual PI3K and histone deacetylase inhibitor CUDC-907, which can downregulate Mcl-1, upregulate Bim, and induce DNA damage, as well as downregulate c-Myc. We establish that CUDC-907 and venetoclax synergistically induce apoptosis in AML cell lines and primary AML patient samples ex vivo. CUDC-907 downregulates CHK1, Wee1, RRM1, and c-Myc, which were found to play a role in venetoclax-induced apoptosis. Interestingly, we find that venetoclax treatment enhances CUDC-907-induced DNA damage potentially through inhibition of DNA repair. In vivo results show that CUDC-907 enhances venetoclax efficacy in an AML cell line derived xenograft mouse model, supporting the development of CUDC-907 in combination with venetoclax for the treatment of AML. 相似文献
4.
5.
6.
Kathleen Van Asten Laurence Slembrouck Siel Olbrecht Lynn Jongen Olivier Brouckaert Hans Wildiers Giuseppe Floris Erik Van Limbergen Caroline Weltens Ann Smeets Robert Paridaens Anita Giobbie-Hurder Meredith M. Regan Giuseppe Viale Beat Thürlimann Ignace Vergote Evangelia Christodoulou Ben Van Calster Patrick Neven 《The oncologist》2019,24(2):165-171
7.
Cameron Buckley Ella Trembizki Robert W. Baird Marcus Chen Basil Donovan Kevin Freeman Namraj Goire Rebecca Guy Monica M. Lahra David Regan David M. Whiley 《Journal of clinical microbiology》2015,53(8):2706-2708
A multitarget PCR was developed for the direct detection of penicillinase-producing Neisseria gonorrhoeae (PPNG). The assay was validated by testing 342 PPNG isolates and 415 clinical samples. The method is suitable for routine detection of PPNG strains. Its multitarget approach reduces the potential for false-negative results caused by sequence variations. 相似文献
8.
9.
Histamine reduces boron neutron capture therapy‐induced mucositis in an oral precancer model 下载免费PDF全文
10.
Hasan K. Siddiqi Brittany Weber Guohai Zhou James Regan Jesse Fajnzylber Kendyll Coxen Heather Corry Xu G. Yu Marcelo DiCarli Jonathan Z. Li Deepak L. Bhatt 《The American journal of medicine》2021,134(4):542-546
BackgroundPatients with coronavirus disease 2019 (COVID-19) have a high prevalence of detectable troponin and myocardial injury. In addition, a subset of patients with COVID-19 has detectable severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral loads. The objective of this study was to understand the relationship among SARS-CoV-2 viremia, detectable troponin, and myocardial injury in hospitalized patients with COVID-19.MethodsSARS-CoV-2 plasma viral load was measured in plasma samples drawn from patients hospitalized for COVID-19 at 2 academic medical centers. Baseline characteristics and clinically obtained high-sensitivity cardiac troponin T (hs-cTnT) values were abstracted from the medical record. The main outcome was detectable hs-cTnT (≥6 ng/mL) and myocardial injury (hs-cTnT ≥14 ng/mL; >99th percentile for assay).ResultsA total of 70 hospitalized patients with COVID-19 were included in this study, with 39% females and median age 58 ± 17 years; 21 patients (30%) were found to have detectable SARS-CoV-2 viral load and were classified in the viremia group. Patients with viremia were significantly older than those without viremia. All of the patients with viremia (100%) had detectable troponin during hospitalization compared with 59% of patients without viremia (P = 0.0003). Myocardial injury was seen in 76% of patients with viremia and 38% of those patients without viremia (P = 0.004).ConclusionsHospitalized patients with COVID-19 with SARS-CoV-2 viremia have a significantly higher prevalence of detectable troponin and myocardial injury during their hospitalization compared with patients who did not. This first report of the relationship among SARS-CoV-2 viremia, detectable troponin, and myocardial injury in patients with COVID-19 points to additional mechanistic pathways that require deeper study to understand the complex interplay among these unique findings, cardiovascular outcomes, and mortality in COVID-19. 相似文献